All lobbying filings

Boehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, Inc. filed a Q2 report for Boehringer Ingelheim USA Corporation on July 21, 2025.

Lobbying for Boehringer Ingelheim USA Corporation · Lobbyists

As filed: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION.

All filings by Boehringer Ingelheim USA Corporation, Formerly Reported as Boehringer Ingelheim Pharmaceuticals, Inc. · Everything Boehringer Ingelheim USA Corporation has reported

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Mar 10, 2026.

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Expenses

$990,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act

Medicare/Medicaid

Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals

Animals

Issues related to Animal Health Issues related to One Health Issues Related to Compounding Animal Drugs from Bulk Substances Far, Food and National Security Act of 2024 (H.R. 8467) Foreign Animal Disease Prevention Surveillance and Rapid Response Act of 2023 (H.R. 3419/S.1666)

Budget/Appropriations

Issues related to FY2026 Appropriations

Bills named in this filing 5

H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S. 832
EPIC Act of 2025
H.R. 8467
Farm, Food, and National Security Act of 2024
H.R. 3419
Foreign Animal Disease Prevention, Surveillance, and Rapid Response Act of 2023
S. 1666
Foreign Animal Disease Prevention, Surveillance, and Rapid Response Act of 2023

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.